Mersana Therapeutics (NASDAQ:MRSN) Releases Earnings Results, Beats Expectations By $0.05 EPS

Mersana Therapeutics (NASDAQ:MRSN) posted its quarterly earnings data on Monday. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05, Zacks reports. The business had revenue of $16.36 million during the quarter, compared to the consensus estimate of $7.71 million. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%.

Mersana Therapeutics Price Performance

Shares of NASDAQ:MRSN opened at $0.51 on Wednesday. The company has a market capitalization of $62.79 million, a PE ratio of -0.83 and a beta of 1.39. The company has a debt-to-equity ratio of 13.35, a quick ratio of 2.35 and a current ratio of 2.35. The stock has a fifty day moving average of $0.82 and a 200-day moving average of $1.56. Mersana Therapeutics has a one year low of $0.46 and a one year high of $6.28.

Analyst Ratings Changes

A number of analysts have commented on MRSN shares. William Blair started coverage on shares of Mersana Therapeutics in a research report on Thursday, February 6th. They set an “outperform” rating on the stock. Wedbush restated an “outperform” rating and issued a $4.00 target price on shares of Mersana Therapeutics in a research report on Monday. Finally, Citigroup began coverage on Mersana Therapeutics in a research report on Friday, November 15th. They set a “buy” rating and a $5.00 price target on the stock. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Mersana Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $4.25.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.